Cite
Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response.
MLA
Pazdera, Ladislav, et al. “Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response.” Cephalalgia, vol. 41, no. 10, Sept. 2021, pp. 1075–88. EBSCOhost, https://doi.org/10.1177/03331024211008401.
APA
Pazdera, L., Cohen, J. M., Ning, X., Campos, V. R., Yang, R., & Pozo-Rosich, P. (2021). Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response. Cephalalgia, 41(10), 1075–1088. https://doi.org/10.1177/03331024211008401
Chicago
Pazdera, Ladislav, Joshua M Cohen, Xiaoping Ning, Verena Ramirez Campos, Ronghua Yang, and Patricia Pozo-Rosich. 2021. “Fremanezumab for the Preventive Treatment of Migraine: Subgroup Analysis by Number of Prior Preventive Treatments with Inadequate Response.” Cephalalgia 41 (10): 1075–88. doi:10.1177/03331024211008401.